A Food and Drug Administration panel opened a new era in medicine Wednesday, unanimously recommending that the agency approve the first treatment that genetically alters a patient's own cells to fight leukemia, transforming them into what scientists call "a living drug" that powerfully bolsters the immune system to shut down the disease.
Trending:
FDA panel recommends approval for gene-altering leukemia treatment